New studies suggest better outcomes when patients are switched to an aromatase inhibitor after two to three years of tamoxifen or when they start adjuvant therapy with an aromatase inhibitor. The breast cancer community discusses the relative efficacy of the various approaches in hormone-sensitive disease. Debu Tripathy, MD, from Dallas' University of Texas Southern Medical Center, offers his take on the pros and cons of the variety aromatase inhibitor-based treatment strategies.
More...
Linear Mode
